Tecentriq Hybreza (atezolizumab / hyaluronidase-tqjs)
Genentech / Roche · PD-L1 Immune Checkpoint Inhibitor (Subcutaneous Formulation)
What is Tecentriq Hybreza? Tecentriq Hybreza is a subcutaneous formulation combining atezolizumab with hyaluronidase-tqjs. It delivers the same active ingredient as Tecentriq IV but as a subcutaneous injection, offering a faster administration option.
About Tecentriq Hybreza
| Brand Name | Tecentriq Hybreza |
| Generic / INN | atezolizumab / hyaluronidase-tqjs |
| Drug Class | PD-L1 Immune Checkpoint Inhibitor (Subcutaneous Formulation) |
| Manufacturer | Genentech / Roche |
| Administration | Subcutaneous injection |
| FDA Approval | 2024 |
| Presentation | Tecentriq Hybreza contains atezolizumab 1875 mg / hyaluronidase-tqjs in a single-dose vial. |
FDA-Approved Uses for Tecentriq Hybreza
The following indications are based on FDA approval as of the last review date. Your oncologist will determine appropriate use based on your specific cancer type, stage, biomarker status, and overall treatment plan.
- All FDA-approved indications for atezolizumab (Tecentriq) where subcutaneous administration is appropriate
How Does Tecentriq Hybreza Work?
Atezolizumab blocks PD-L1 to restore immune T cell activity against tumor cells. Hyaluronidase-tqjs is an enzyme that temporarily breaks down hyaluronan in subcutaneous tissue, enabling rapid absorption and dispersion of the drug when injected subcutaneously rather than intravenously.
Dosage & Administration
1875 mg administered as a subcutaneous injection over approximately 7 minutes. Schedule depends on indication and combination regimen. The prescribing oncologist will determine the appropriate frequency.
Dosing for oncology medications is individualized by the treating oncologist or oncology pharmacist. Do not adjust dosing without consulting your healthcare team. The information on this page is educational only and does not replace the official prescribing information or your provider's guidance.
Warnings, Precautions & Side Effects
General Warning
Immune-mediated adverse reactions as with IV atezolizumab. Local injection site reactions possible. Embryo-fetal toxicity.
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Immune-mediated endocrinopathies
- Embryo-fetal toxicity
Common Side Effects
- Injection site reactions
- Fatigue
- Decreased appetite
- Nausea
- Rash
- Constipation
This is not a complete list. Report any new or worsening symptoms to your oncologist or healthcare provider promptly.
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze.
Oncology medications require careful handling. BiologicHealthPlus provides cold-chain specialty delivery with temperature monitoring for medications that require refrigeration. Do not use the medication if the storage chain has been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Tecentriq Hybreza is a specialty oncology medication covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage varies by plan, indication, and formulary tier. BiologicHealthPlus verifies benefits at no cost to patients.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Tecentriq Hybreza. Our team handles the full prior authorization process — submitting clinical documentation, peer-to-peer reviews when needed, and appeals — at no cost to patients or providers.
🏥 Medicare & Medicaid
Medicare coverage for oncology medications depends on route of administration. Intravenous oncology medications are typically covered under Medicare Part B (medical benefit) when administered in a clinical setting. Subcutaneous formulations may be covered under Part B or Part D depending on administration circumstances. Medicaid coverage varies by state.
🆓 Patient Assistance Programs
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. BiologicHealthPlus can assess your eligibility and help with the application process. Contact our team for a confidential eligibility review.
Prior Authorization Guide Patient Assistance Programs Insurance & Savings Medication Costs
Frequently Asked Questions About Tecentriq Hybreza
Tecentriq Hybreza is a subcutaneous injection formulation of atezolizumab combined with hyaluronidase-tqjs, manufactured by Genentech/Roche. It delivers the same active checkpoint inhibitor as Tecentriq IV but is injected under the skin instead of given intravenously.
The subcutaneous injection takes approximately 7 minutes, significantly faster than IV Tecentriq infusions which can take 30–60 minutes.
Tecentriq Hybreza contains the same active ingredient (atezolizumab) as Tecentriq. The key difference is the formulation: Tecentriq Hybreza is given subcutaneously, while Tecentriq is an intravenous infusion.
Coverage depends on the insurance plan and indication. As a newer subcutaneous formulation, prior authorization requirements apply. BiologicHealthPlus can complete a benefits verification on your behalf.
Related Medications & Conditions
Related Medications
Tecentriq · Keytruda Qlex · Keytruda · Atezolizumab
Related Conditions
Non-small cell lung cancer · Urothelial carcinoma · Hepatocellular carcinoma